Onglyza approved for use in renal impairment

The licence for Onglyza (saxagliptin) has been extended to allow its use in patients with type II diabetes and moderate or severe renal impairment. Onglyza, a dipeptidyl peptidase 4 (DPP-4) inhibitor, is the first in its class to be licensed for use in this patient population.

Onglyza now an option in diabetes with renal impairment
Onglyza now an option in diabetes with renal impairment

No dosage adjustment is required for Onglyza in mild renal impairment; however, in moderate to severe impairment a reduced dose of 2.5mg once daily is recommended. Renal function should be monitored prior to initiation of therapy and periodically thereafter. A new 2.5mg tablet has been launched to facilitate dosing in moderate or severe renal impairment.

Caution is advised in patients with severe renal impairment and use in patients with end-stage renal disease (ESRD) requiring dialysis is not recommended.

Approval for the licence extension was based on the results of a 12-week randomised controlled study, which showed that saxagliptin 2.5mg is a well-tolerated treatment option for patients with inadequately controlled type II diabetes and renal impairment.

The 12-week study involved 170 adults with type II diabetes, HbA1c 7-11% and creatinine clearance <50ml/minute who were randomised to saxagliptin 2.5mg once daily or placebo. Significantly greater reductions in HbA1c from baseline to week 12 were observed in the saxagliptin group than in the placebo group (adjusted mean treatment difference -0.42% [p=0.007]).

Saxagliptin was generally well tolerated with a similar incidence of hypoglycaemia in the saxagliptin and placebo groups (20% vs 22.4%, respectively). The proportion of patients experiencing an adverse effect was greater among those with severe renal impairment or ESRD than among those with moderate impairment.

View Onglyza drug record

Further Information: AstraZeneca

Read these next

Vipidia and Vipdomet: two new products for type II diabetes

Takeda has launched Vipidia and Vipdomet, two new products...

News in brief - October 2013

Other new launches, licence changes and updates relevant...

Onglyza approved for triple oral therapy

Onglyza (saxagliptin) can now be used in combination...

Pancreatitis risk with DPP4 inhibitors

Acute pancreatitis is now listed as a possible adverse...

Januvia no longer contraindicated in renal impairment

Januvia (sitagliptin) can now be used at a lower dose...

Onglyza licence extended for use in combination with insulin

Onglyza (saxagliptin) can now be prescribed in combination...

Galvus licensed for use in renal impairment

Galvus (vildagliptin) is now suitable for use with...

New DPP4 inhibitor launched

Bristol Myers-Squibb and AstraZeneca have launched...

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.